

Vanita Noronha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2486338/publications.pdf>

Version: 2024-02-01

226
papers

2,885
citations

257357

24
h-index

214721

47
g-index

227
all docs

227
docs citations

227
times ranked

3549
citing authors

#	ARTICLE	IF	CITATIONS
1	Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1064-1072.	0.8	229
2	Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1234-1242.	0.8	178
3	Primary non-Hodgkin's lymphoma of the liver. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 199-207.	2.0	172
4	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017, 22, 1056-1066.	1.9	122
5	Crizotinib: A comprehensive review. <i>South Asian Journal of Cancer</i> , 2013, 2, 91.	0.2	115
6	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. <i>Cancer Cell</i> , 2018, 34, 792-806.e5.	7.7	102
7	Frequency of EGFR Mutations in 907 Lung Adenocarcinoma Patients of Indian Ethnicity. <i>PLoS ONE</i> , 2013, 8, e76164.	1.1	94
8	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. <i>Cancer</i> , 2019, 125, 3184-3197.	2.0	73
9	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 86.	1.3	71
10	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. <i>Oral Oncology</i> , 2015, 51, 279-286.	0.8	65
11	Lung cancer in the Indian subcontinent. <i>South Asian Journal of Cancer</i> , 2016, 05, 095-103.	0.2	63
12	Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. <i>Neuro-Oncology</i> , 2006, 8, 280-283.	0.6	62
13	EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. <i>PLoS ONE</i> , 2013, 8, e61561.	1.1	61
14	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. <i>The Lancet Global Health</i> , 2020, 8, e1213-e1222.	2.9	57
15	A fresh look at oncology facts on south central Asia and SAARC countries. <i>South Asian Journal of Cancer</i> , 2012, 01, 01-04.	0.2	49
16	Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. <i>Lancet Oncology</i> , The, 2006, 7, 270-271.	5.1	48
17	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. <i>ESMO Open</i> , 2017, 2, e000168.	2.0	48
18	>EGFR >mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1859-1863.	1.0	44

#	ARTICLE	IF	CITATIONS
19	Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. <i>Urology Annals</i> , 2012, 4, 150.	0.3	39
20	Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 1-11.	1.3	38
21	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non-Small-Cell Lung Cancer. <i>Journal of Global Oncology</i> , 2017, 3, 208-217.	0.5	33
22	Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2903-2908.	1.0	29
23	Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. <i>Oral Oncology</i> , 2018, 76, 52-60.	0.8	29
24	Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 1-10.	1.3	29
25	COVID-19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. <i>Cancer Medicine</i> , 2020, 9, 8747-8753.	1.3	29
26	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. <i>PLoS ONE</i> , 2016, 11, e0160752.	1.1	28
27	Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer. <i>Oncology Research</i> , 2016, 23, 183-195.	0.6	26
28	Salvage surgery in head and neck cancer: Does it improve outcomes?. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1052-1058.	0.5	25
29	The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients. <i>Chemotherapy Research and Practice</i> , 2014, 2014, 1-4.	1.6	24
30	A systematic approach to diagnosis of cystic brain lesions. <i>South Asian Journal of Cancer</i> , 2013, 2, 98.	0.2	24
31	Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature. <i>Clinical Colorectal Cancer</i> , 2005, 5, 283-286.	1.0	23
32	Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus. <i>Chemotherapy Research and Practice</i> , 2014, 2014, 1-6.	1.6	23
33	Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 272-281.	0.8	22
34	Analysis of solid tumor mutation profiles in liquid biopsy. <i>Cancer Medicine</i> , 2018, 7, 5439-5447.	1.3	21
35	Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 6007-6007.	0.8	20
36	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 161-165.	0.1	20

#	ARTICLE	IF	CITATIONS
37	Noadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). International Journal of Surgical Oncology, 2016, 2016, 1-8.	0.3	18
38	Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. Expert Review of Anticancer Therapy, 2020, 20, 17-29.	1.1	17
39	Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. Oral Oncology, 2020, 105, 104673.	0.8	17
40	A real-world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Medicine, 2021, 10, 1525-1534.	1.3	17
41	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	0.8	16
42	Aprepitant for Cough Suppression in Advanced Lung Cancer. Chest, 2020, 157, 1647-1655.	0.4	15
43	Noadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review. Journal of Cancer Research and Therapeutics, 2015, 11, 1003.	0.3	15
44	Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Results—A Rare Case Report with a Diagnostic and Therapeutic Challenge. Pathology and Oncology Research, 2012, 18, 1101-1106.	0.9	14
45	Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Supportive Care in Cancer, 2016, 24, 1595-1602.	1.0	14
46	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. Journal of the National Cancer Institute, 2021, 113, 1228-1237.	3.0	14
47	Systemic therapy for limited stage small cell lung carcinoma. Journal of Thoracic Disease, 2020, 12, 6275-6290.	0.6	13
48	Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. Oncotarget, 2021, 12, 578-588.	0.8	13
49	Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases. Ecancermedicalscience, 2017, 11, 779.	0.6	12
50	Prognostic and predictive significance of nuclear HIF1 α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab. British Journal of Cancer, 2020, 123, 1757-1766.	2.9	12
51	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. Oncotarget, 2020, 11, 399-408.	0.8	12
52	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian Journal of Cancer, 2016, 05, 182-185.	0.2	12
53	Low doses in immunotherapy: Are they effective?. Cancer Research Statistics and Treatment, 2019, 2, 54.	0.1	12
54	High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer. Medical Oncology, 2014, 31, 188.	1.2	11

#	ARTICLE	IF	CITATIONS
55	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. <i>Oral Oncology</i> , 2017, 75, 54-60.	0.8	11
56	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. <i>South Asian Journal of Cancer</i> , 2017, 06, 011-014.	0.2	11
57	Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. <i>Indian Journal of Cancer</i> , 2017, 54, 601.	0.2	11
58	Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. <i>Journal of Oncology Practice</i> , 2017, 13, e574-e581.	2.5	10
59	Immune checkpoint inhibitors in patients with solid tumors and poor performance status. <i>Medicine (United States)</i> , 2021, 100, e25115.	0.4	10
60	Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. <i>Oral Oncology</i> , 2021, 122, 105517.	0.8	10
61	Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. <i>Indian Journal of Cancer</i> , 2019, 56, 54.	0.2	10
62	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. <i>Frontiers in Oncology</i> , 2021, 11, 752018.	1.3	10
63	Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. <i>JCO Global Oncology</i> , 2022, , .	0.8	10
64	Primary mediastinal seminoma; resistance and relapse: An aggressive entity. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 309-312.	0.1	9
65	Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy. <i>Indian Journal of Cancer</i> , 2014, 51, 20.	0.2	9
66	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. <i>Oral Oncology</i> , 2020, 100, 104455.	0.8	9
67	Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6000-6000.	0.8	9
68	Stage IV lung cancer: Is cure possible?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 121.	0.1	8
69	Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2014, 35, 75-78.	0.1	8
70	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 496.e9-496.e15.	0.8	8
71	Sunitinib-induced thrombotic microangiopathy. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 6.	0.3	8
72	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. <i>South Asian Journal of Cancer</i> , 2018, 07, 249-252.	0.2	8

#	ARTICLE	IF	CITATIONS
73	Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist. Indian Dermatology Online Journal, 2014, 5, 89.	0.2	7
74	Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 1049.	0.3	7
75	Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian Journal of Cancer, 2016, 05, 067-069.	0.2	7
76	Thyroid cancer in Gardner's syndrome: Case report and review of literature. South Asian Journal of Cancer, 2012, 01, 43-47.	0.2	7
77	A study to assess the feasibility of introducing early palliative care in ambulatory patients with advanced lung cancer. Indian Journal of Palliative Care, 2017, 23, 261.	1.0	7
78	Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey. South Asian Journal of Cancer, 2018, 07, 203-206.	0.2	7
79	G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer. Journal of Geriatric Oncology, 2022, 13, 720-730.	0.5	7
80	High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy. Cancer Management and Research, 2014, 6, 261.	0.9	6
81	Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers. Oral Oncology, 2015, 51, e91-e92.	0.8	6
82	Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement. Journal of Gastrointestinal Cancer, 2016, 47, 294-304.	0.6	6
83	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. Clinical Genitourinary Cancer, 2017, 15, e345-e355.	0.9	6
84	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine, 2019, 9, 19-25.	3.2	6
85	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. BMJ Open, 2021, 11, e043628.	0.8	6
86	Distress Screening in Head and Neck Cancer Patients Planned for Cancer-Directed Radiotherapy. Laryngoscope, 2021, 131, 2023-2029.	1.1	6
87	Tolvaptan. South Asian Journal of Cancer, 2014, 03, 182-184.	0.2	6
88	Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. Indian Journal of Cancer, 2017, 54, 678.	0.2	6
89	An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome. South Asian Journal of Cancer, 2020, 09, 06-12.	0.2	6
90	Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e129-e137.	0.7	6

#	ARTICLE	IF	CITATIONS
91	Comprehensive Development and Implementation of Good Laboratory Practice for NGS Based Targeted Panel on Solid Tumor FFPE Tissues in Diagnostics. <i>Diagnostics</i> , 2022, 12, 1291.	1.3	6
92	Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2013, 34, 24.	0.1	5
93	Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?. <i>Urology Annals</i> , 2014, 6, 18.	0.3	5
94	Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. <i>Cancer Letters</i> , 2017, 400, 267-275.	3.2	5
95	Neoadjuvant chemotherapy in geriatric head and neck cancers. <i>Head and Neck</i> , 2017, 39, 886-892.	0.9	5
96	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study. <i>Ecancermedalscience</i> , 2018, 12, 876.	0.6	5
97	Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1427-1436.	0.8	5
98	Advances in pharmacotherapy for head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2007-2018.	0.9	5
99	Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings. <i>Ecancermedalscience</i> , 2020, 14, 1038.	0.6	5
100	Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2015, 36, 238-242.	0.1	5
101	Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. <i>South Asian Journal of Cancer</i> , 2018, 07, 226-230.	0.2	5
102	The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours: A real-world multicentric study from India. <i>International Journal of Cancer</i> , 2021, , .	2.3	5
103	Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes. <i>Radiotherapy and Oncology</i> , 2022, 170, 151-158.	0.3	5
104	Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 751-759.	1.1	5
105	Chicken pox infection in patients undergoing chemotherapy: A retrospective analysis from a tertiary care center in India. <i>Journal of Infection and Public Health</i> , 2017, 10, 8-13.	1.9	4
106	Making the Best of Limited Resources: Improving Outcomes in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 279-289.	1.8	4
107	Intensity-modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. <i>Head and Neck</i> , 2021, 43, 2045-2057.	0.9	4
108	Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study. <i>Cancer Medicine</i> , 2021, 10, 6725-6735.	1.3	4

#	ARTICLE	IF	CITATIONS
109	A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.. Journal of Clinical Oncology, 2019, 37, 6054-6054.	0.8	4
110	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. South Asian Journal of Cancer, 2017, 06, 186-189.	0.2	4
111	Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer. South Asian Journal of Cancer, 2017, 06, 143-146.	0.2	4
112	Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). Ecancermedalscience, 2021, 15, 1325.	0.6	4
113	The X factor: An Indian perspective on women in academic oncology. Journal of Cancer Research and Therapeutics, 2013, 9, 552.	0.3	3
114	Case of childhood laryngeal papillomatosis with metastatic carcinoma esophagus in adulthood. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 34-37.	0.1	3
115	Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers. Oral Oncology, 2017, 70, 73-74.	0.8	3
116	Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. Asian Journal of Oncology, 2017, 03, 039-044.	0.2	3
117	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. Journal of Global Oncology, 2017, 3, 346-359.	0.5	3
118	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. BMJ Open, 2021, 11, e041345.	0.8	3
119	Adolescentâ€œadult nonmetastatic Ewing sarcomaâ€œ”Experience from a large developing country. Pediatric Blood and Cancer, 2021, 68, e29081.	0.8	3
120	ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients. Cancer Medicine, 2021, 10, 4948-4956.	1.3	3
121	Weight loss and its impact on outcome in head and cancer patients during chemo-radiation. Oral Oncology, 2021, 122, 105522.	0.8	3
122	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.3	3
123	Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 172-175.	0.1	3
124	Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Translational Oncology, 2022, 22, 101461.	1.7	3
125	A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Nonâ€œSmall Cell Lung Cancer. Clinical Pharmacology in Drug Development, 2017, 6, 234-239.	0.8	2
126	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexedâ€œcarboplatin chemotherapy. Ecancermedalscience, 2017, 11, 776.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Metastatic Renal Cell Cancerâ€”Systemic Therapy. Indian Journal of Surgical Oncology, 2018, 9, 97-104.	0.3	2
128	A competing risk analysis of death patterns in male genitourinary cancer. Cancer Reports, 2020, 3, e1174.	0.6	2
129	Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxaneâ€”based induction chemotherapy and concurrent chemoâ€”radiotherapy in the modern era. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2020, 6, 25-33.	0.7	2
130	Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Translational Oncology, 2021, 14, 101111.	1.7	2
131	Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre. Annals of Diagnostic Pathology, 2021, 53, 151763.	0.6	2
132	NACT in locally advanced oral cancers : Does HPV make a difference?. Journal of Clinical Oncology, 2015, 33, e17068-e17068.	0.8	2
133	Patterns of EGFR testing for lung cancer among tertiary care centers in India.. Journal of Clinical Oncology, 2015, 33, e19114-e19114.	0.8	2
134	Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.. Journal of Clinical Oncology, 2017, 35, 6018-6018.	0.8	2
135	Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers. Journal of Community and Supportive Oncology, 2016, 14, 412-419.	0.1	2
136	Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 249-254.	0.1	2
137	Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?. Journal of Clinical Oncology, 2013, 31, 6085-6085.	0.8	2
138	Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study. Cureus, 2017, 9, e1149.	0.2	2
139	Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!. South Asian Journal of Cancer, 2020, 09, 195-198.	0.2	2
140	Pembrolizumab weight based dosing â€” A call for policy change. Indian Journal of Medical and Paediatric Oncology, 2022, 43, 306-310.	0.1	2
141	Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with <sc>onceâ€”week</sc> versus <sc>onceâ€”everyâ€”3â€”weeks</sc> cisplatin. Cancer Medicine, 2022, 11, 3939-3948.	1.3	2
142	Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers. Oral Oncology, 2022, 127, 105824.	0.8	2
143	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. Oral Oncology, 2022, 128, 105816.	0.8	2
144	Translation and Validation of COST - FACIT (Version 2) Questionnaire into Hindi and Marathi to Assess Financial Toxicity in Indian Cancer Patients. South Asian Journal of Cancer, 2022, 11, 097-104.	0.2	2

#	ARTICLE	IF	CITATIONS
145	Rare metastatic prostatic malignancy: A case report and approach to management. Indian Journal of Medical and Paediatric Oncology, 2011, 32, 233.	0.1	1
146	A diagnostic dilemma in a patient with lymphoma. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 114-116.	0.1	1
147	Technically unresectable recurrent oral cancers: Is NACT the answer?. Oral Oncology, 2016, 56, e12-e14.	0.8	1
148	P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC. Journal of Thoracic Oncology, 2017, 12, S1223.	0.5	1
149	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
150	The role of chemotherapy in patients with small cell lung cancer and poor performance status. Acta Oncologica, 2020, 59, 1520-1527.	0.8	1
151	Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis. Journal of the Egyptian National Cancer Institute, 2021, 33, 12.	0.6	1
152	Systemic Therapy in Thyroid Cancer. Indian Journal of Surgical Oncology, 2022, 13, 68-80.	0.3	1
153	An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings. Ecancermedicalscience, 2021, 15, 1274.	0.6	1
154	782 PATTERNS OF FAILURE AND ADEQUACY OF CLINICAL TARGET VOLUME (CTV) MARGINS IN PATIENTS TREATED WITH DEFINITIVE CHEMO-RADIATION IN ESOPHAGEAL CANCER. Ecological Management and Restoration, 2021, 34, .	0.2	1
155	Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy. Therapeutic Advances in Drug Safety, 2021, 12, 204209862199128.	1.0	1
156	Effect of EGFR mutations on outcomes in NSCLC with brain metastases.. Journal of Clinical Oncology, 2016, 34, e20644-e20644.	0.8	1
157	An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. Biometrical Letters, 2018, 55, 1-15.	0.4	1
158	Aggressive surgery in palliative setting of lung cancer: Is it helpful?. Indian Journal of Palliative Care, 2016, 22, 504.	1.0	1
159	Geriatric oncology: The need of the hour. South Asian Journal of Cancer, 2013, 02, 200-201.	0.2	1
160	An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma. South Asian Journal of Cancer, 2019, 08, 159-165.	0.2	1
161	Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer. South Asian Journal of Cancer, 2018, 07, 194-202.	0.2	1
162	Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience.. Journal of Clinical Oncology, 2013, 31, e20678-e20678.	0.8	1

#	ARTICLE	IF	CITATIONS
163	A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.. Journal of Clinical Oncology, 2014, 32, 6017-6017.	0.8	1
164	Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors. Journal of Cancer Research and Therapeutics, 2016, 13, 1023-1026.	0.3	1
165	Phase III open label randomized controlled trial comparing intravenous iron sucrose to oral ferrous sulphate (without erythropoiesis stimulating agents) in the treatment of cancer related iron deficiency anemia.. Journal of Clinical Oncology, 2016, 34, 10136-10136.	0.8	1
166	Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience.. Journal of Clinical Oncology, 2017, 35, e20628-e20628.	0.8	1
167	Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.. Journal of Clinical Oncology, 2018, 36, e15065-e15065.	0.8	1
168	Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid. South Asian Journal of Cancer, 2019, 08, 185-188.	0.2	1
169	Palliative chemotherapy in carcinoma nasopharynx. South Asian Journal of Cancer, 2019, 08, 173-177.	0.2	1
170	Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2019, 08, 211-225.	0.2	1
171	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	0.8	1
172	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. South Asian Journal of Cancer, 2020, 09, 23-26.	0.2	1
173	Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian Journal of Cancer, 2020, 09, 180-182.	0.2	1
174	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study. Ecancermedalscience, 2021, 15, 1318.	0.6	1
175	Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review. South Asian Journal of Cancer, 0, , .	0.2	1
176	Addressing the Needs of Older Adults With Cancer in Low- and Middle-Income Settings. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 384-393.	1.8	1
177	Change in Pattern of Failure in Head and Neck Cancer. Journal of Clinical Oncology, 0, , .	0.8	1
178	Oesophageal carcinoma presenting with a synchronous asymptomatic colon carcinoma. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 117.	0.1	0
179	Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Reports in Oncology, 2016, 9, 506-515.	0.3	0
180	Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature. Lung Cancer Management, 2016, 5, 21-27.	1.5	0

#	ARTICLE	IF	CITATIONS
181	Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer. IDCases, 2016, 3, 8-9.	0.4	0
182	P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial. Journal of Thoracic Oncology, 2017, 12, S1225.	0.5	0
183	P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1229-S1230.	0.5	0
184	Evolving Management Strategies and Controversies in Early-Stage Lung Cancer. Journal of Oncology Practice, 2017, 13, 79-81.	2.5	0
185	Choices. Acta Oncol ³ gica, 2020, 59, 797-798.	0.8	0
186	Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer. Journal of Gastrointestinal Cancer, 2020, , 1.	0.6	0
187	The Day My Gut Feeling Led Me Astray. New England Journal of Medicine, 2020, 382, 1880-1881.	13.9	0
188	Reply to T. Tanaka et al and F. Liang. Journal of Clinical Oncology, 2020, 38, 844-846.	0.8	0
189	Oral metronomic therapy in head and neck cancer – Authors' reply. The Lancet Global Health, 2021, 9, e21.	2.9	0
190	Study of Treatment Outcome in Adults with TFE-Related RCC. South Asian Journal of Cancer, 2021, 10, 92-96.	0.2	0
191	An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian Journal of Surgical Oncology, 2022, 13, 61-67.	0.3	0
192	287 OUTCOMES OF DEFINITIVE CHEMORADIOTHERAPY IN LONG SEGMENT ESOPHAGEAL CANCERS FROM A TERTIARY CANCER CENTRE IN INDIA. Ecological Management and Restoration, 2021, 34, .	0.2	0
193	The changing landscape of hormonal therapy in castration-resistant prostate cancer. South Asian Journal of Cancer, 2012, 01, 53-55.	0.2	0
194	The changing landscape of cancer in rural setting. South Asian Journal of Cancer, 2012, 01, 58-58.	0.2	0
195	The cure for a racing heart. South Asian Journal of Cancer, 2013, 2, 169.	0.2	0
196	Neoadjuvant DCF in resectable esophageal cancer: Single-center experience.. Journal of Clinical Oncology, 2013, 31, 124-124.	0.8	0
197	Quality of life and safety profile of pemetrexed-platinum doublet in Indian adult chemo-naive NSCLC patients.. Journal of Clinical Oncology, 2013, 31, e19118-e19118.	0.8	0
198	Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?. Journal of Clinical Oncology, 2013, 31, e17027-e17027.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Confusion worse confounded. South Asian Journal of Cancer, 2013, 02, 278-278.	0.2	0
200	Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.. Journal of Clinical Oncology, 2014, 32, e17033-e17033.	0.8	0
201	Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 132-132.	0.1	0
202	Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.. Journal of Clinical Oncology, 2015, 33, e17534-e17534.	0.8	0
203	A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC.. Journal of Clinical Oncology, 2015, 33, e17532-e17532.	0.8	0
204	Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India.. Journal of Clinical Oncology, 2015, 33, e15553-e15553.	0.8	0
205	Prognostic importance of pretreatment sodium levels in patients of NSCLC treated with pemetrexed-platinum doublet chemotherapy.. Journal of Clinical Oncology, 2015, 33, e18510-e18510.	0.8	0
206	A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 74-78.	0.1	0
207	Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO's antiemetic clinical guideline.. Journal of Clinical Oncology, 2016, 34, e18230-e18230.	0.8	0
208	Toxicity, tolerance and outcomes of carboplatin based CRTT (concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CRTT.. Journal of Clinical Oncology, 2016, 34, e17539-e17539.	0.8	0
209	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.1	0
210	Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer -Real World Experience. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 46-51.	0.1	0
211	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
212	Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.. Journal of Clinical Oncology, 2018, 36, e18022-e18022.	0.8	0
213	Influence of hypothyroidism post chemo radiation on outcomes in head and neck cancer.. Journal of Clinical Oncology, 2018, 36, e18066-e18066.	0.8	0
214	Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy. South Asian Journal of Cancer, 2018, 07, 213-214.	0.2	0
215	First-line immunotherapy in advanced non-small-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 461.	0.1	0
216	QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.. Journal of Clinical Oncology, 2019, 37, e17519-e17519.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer. South Asian Journal of Cancer, 2020, 09, 47-49.	0.2	0
218	Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.. Journal of Clinical Oncology, 2020, 38, 12092-12092.	0.8	0
219	Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2020, 38, e15172-e15172.	0.8	0
220	Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian Journal of Surgical Oncology, 2022, 13, 81-86.	0.3	0
221	Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2020, 09, 67-68.	0.2	0
222	Lymphopenia during chemoradiation-foe or friend. Ecancermedalscience, 2020, 14, 1109.	0.6	0
223	Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. Ecancermedalscience, 2020, 14, 1136.	0.6	0
224	Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes. Oral Oncology, 2022, 125, 105709.	0.8	0
225	Older patients with cancer require and deserve more!. Indian Journal of Cancer, 2021, 58, 479.	0.2	0
226	Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Results from a Phase IV study in India. Indian Journal of Cancer, 2022, 59, 1.	0.2	0